Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Diéras

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
Cytometry|October 12, 2000
Differential expression of Bax and Bcl-2 in the assessment of cellular dynamics in fine-needle samples of primary breast carcinomasZ Maciorowski, J Klijanienko, E Padoy, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2012
Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic studyV Diéras, A Lortholary, V Laurence, et al.
The Journal of Infusional Chemotherapy|July 1, 1996
First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancerE Garcia-Giralt, P Beuzeboc, D Deffontaines, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2008
Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapyV Diéras, S Limentani, G Romieu, et al.
Gynecologic Oncology|August 1, 1997
Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinomaJ Y Pierga, V Diéras, P Beuzeboc, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2003
Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical responseJ-Y Pierga, E Mouret, V Laurence, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2014
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIAI E Krop, N U Lin, K Blackwell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2012
Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapyA Awada, L Dirix, L Manso Sanchez, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|February 3, 1999
Is primary chemotherapy useful for all patients with primary invasive breast cancer?S M Scholl, P Beuzeboc, A L Harris, et al.
Cancer|March 27, 2001
Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapyJ Y Pierga, B Asselain, M Jouve, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
Cytometry|October 12, 2000
Differential expression of Bax and Bcl-2 in the assessment of cellular dynamics in fine-needle samples of primary breast carcinomasZ Maciorowski, J Klijanienko, E Padoy, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2012
Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic studyV Diéras, A Lortholary, V Laurence, et al.
The Journal of Infusional Chemotherapy|July 1, 1996
First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancerE Garcia-Giralt, P Beuzeboc, D Deffontaines, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2008
Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapyV Diéras, S Limentani, G Romieu, et al.
Gynecologic Oncology|August 1, 1997
Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinomaJ Y Pierga, V Diéras, P Beuzeboc, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2003
Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical responseJ-Y Pierga, E Mouret, V Laurence, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2014
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIAI E Krop, N U Lin, K Blackwell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2012
Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapyA Awada, L Dirix, L Manso Sanchez, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|February 3, 1999
Is primary chemotherapy useful for all patients with primary invasive breast cancer?S M Scholl, P Beuzeboc, A L Harris, et al.
Cancer|March 27, 2001
Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapyJ Y Pierga, B Asselain, M Jouve, et al.
Pageof 6